Virtual clinical trials are Science 37’s bread and butter. We believe this decentralized approach can accelerate patient recruitment and result in a more diverse group of participants. But do others believe in the power of this new model?
It turns out that the answer is yes. It’s been reassuring and somewhat gratifying to discover that so many others — including giants of the pharmaceutical industry — have taken notice and want to partner with us on this virtual journey. As we’ve said before, this ride isn’t without its bumps, but we’re glad to see that we’re not the only ones who envision a future where researchers and patients can improve the world of clinical research together.
The latest evidence comes from Nature Biotechnology, where writer Eric Smalley explores the pharmaceutical industry’s embrace of virtual clinical trials through the lens of UCB Biosciences. UCB is the latest company to partner with Science 37, and the partnership has even changed UCB’s approach to research.
Changing Minds, Changing Approaches
One of the first conditions that Science 37 and UCB are joining forces to explore through research is restless leg syndrome in adolescents. Before, the company avoided recruiting teenage patients for practicality reasons. Going the traditional route to recruit enough patients for this study would have taken seven or eight years. Partnering with Science 37, UCB expects recruitment to be finished in 18 months.
“Speed is good for everyone. The FDA likes things to be done faster; the patients like the cures to be brought to them faster,” says Noah Craft, Science 37’s CEO.
Iris Lowe-Friedrich, UCB’s chief medical officer, said that “We are really changing our paradigm from the conventional setup to [the virtual model] whenever possible and wherever possible.”
For those of you without access, read a PDF of the full article here.